| Symbol | SMMT |
|---|---|
| Name | SUMMIT THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 601 BRICKELL KEY DRIVE,SUITE 1000, MIAMI, Florida, 33131, United States |
| Telephone | +1 305 - 203-2034 |
| Fax | — |
| — | |
| Website | https://www.smmttx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001599298 |
| Description | Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. Additional info from NASDAQ: |
2026-08-12 13:22
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Read more
2026-08-05 11:00
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Read more
2026-07-27 12:52
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
Read more
2026-07-23 20:34
(99% Neutral) SUMMIT THERAPEUTICS INC. (SMMT) Announces Business Combination
Read more
2026-07-23 20:07
(10% Negative) SUMMIT THERAPEUTICS INC. (SMMT) Announces Delay in results Trials for Western Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more
2026-07-23 17:34
New Form 424B5 - Summit Therapeutics Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001193125-26-314210 <b>Size:</b> 781 KB
Read more
2026-07-22 20:30
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Read more
2026-07-22 11:10
(10% Negative) SUMMIT THERAPEUTICS INC. (SMMT) Announces Delay in analysis Trials for progression-free survival (PFS) Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more
2026-07-22 10:30
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Read more
2026-07-14 13:08
Summit Plc - Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients W… | Phase2 | Phase II | Not_Yet_Recruiting | 2027-02-07 | 2030-05-01 | ClinicalTrials.gov |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Pat… | Phase2 | Phase II | Not_Yet_Recruiting | 2027-01-16 | 2032-11-28 | ClinicalTrials.gov |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chem… | Phase2 | Non Small Cell Lung Cancer | Not_Yet_Recruiting | 2026-11-01 | 2032-04-01 | ClinicalTrials.gov |
| NCT07359456 | Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastati… | Phase2 | Metastatic Colorectal Cancer | Not_Yet_Recruiting | 2026-08-31 | 2033-08-01 | ClinicalTrials.gov |
| NCT07732374 | Long-Term Outcomes Following HBOT | Phase2 | Traumatic Brain Injury | Recruiting | 2026-06-18 | 2027-06-18 | ClinicalTrials.gov |
| NCT07555093 | A Study of Multiple Micronutrient Supplementation (MMS) to Increase Adherence W… | Na | Pregnancy | Recruiting | 2026-06-13 | 2027-06-01 | ClinicalTrials.gov |
| NCT07607301 | Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Met… | Na | Workshop | Recruiting | 2026-06-04 | 2027-03-01 | ClinicalTrials.gov |
| NCT07619339 | A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2026-05-27 | 2029-05-01 | ClinicalTrials.gov |
| NCT07264075 | Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalima… | Phase3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Recruiting | 2026-05-05 | 2030-05-01 | ClinicalTrials.gov |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | Phase2 | Lung Cancer (NSCLC) | Recruiting | 2026-05-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT07535463 | A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People … | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2026-04-10 | 2028-04-01 | ClinicalTrials.gov |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People Wi… | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2026-04-09 | 2028-04-01 | ClinicalTrials.gov |
| NCT07516925 | A Study of Ivonescimab in People With Leiomyosarcoma | Phase2 | Leiomyosarcoma | Recruiting | 2026-04-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT07057791 | Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small… | Phase2 | Extensive Stage Lung Small Cell Cancer | Recruiting | 2026-03-30 | 2030-01-01 | ClinicalTrials.gov |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic … | Phase2 | Metastatic Esophageal Adenocarcinoma | Recruiting | 2025-11-20 | 2028-09-01 | ClinicalTrials.gov |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and… | Phase2 | Advanced Head and Neck Squamous Cell Carcinoma | Recruiting | 2025-11-18 | 2030-11-01 | ClinicalTrials.gov |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients … | Phase3 | Metastatic Colorectal Cancer (CRC) | Recruiting | 2025-11-18 | 2029-11-30 | ClinicalTrials.gov |
| NCT07070466 | Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Phase2 | Stomach Cancer Stage IV | Recruiting | 2025-10-10 | 2028-09-01 | ClinicalTrials.gov |
| NCT06529718 | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients | Phase2 | Biliary Tract Cancer | Recruiting | 2025-10-09 | 2029-01-30 | ClinicalTrials.gov |
| NCT07214415 | Veterans' Cognitive Function, Mental Health, and Quality of Life After Hyperbar… | Phase2 | TBI Traumatic Brain Injury | Recruiting | 2025-10-01 | 2026-09-15 | ClinicalTrials.gov |
| NCT07126041 | Scalable Public Health Empowerment, Research, and Education Sites (SPHERES) | Na | Pregnancy | Not_Yet_Recruiting | 2025-08-14 | 2027-03-31 | ClinicalTrials.gov |
| NCT06959550 | Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients Wi… | Phase2 | Metastatic Colorectal Cancer | Recruiting | 2025-07-28 | 2030-07-01 | ClinicalTrials.gov |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Pa… | Phase2 | TNBC | Recruiting | 2025-07-25 | 2032-11-01 | ClinicalTrials.gov |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | Phase2 | Thymus Carcinoma | Recruiting | 2025-07-15 | 2028-06-17 | ClinicalTrials.gov |
| NCT06940518 | Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clea… | Phase2 | Ivonescimab | Recruiting | 2025-07-02 | 2030-01-19 | ClinicalTrials.gov |
| NCT06840834 | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patien… | Phase2 | Pleural Mesotheliomas | Recruiting | 2025-06-30 | 2028-03-31 | ClinicalTrials.gov |
| NCT06925724 | A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Phase2 | Endometrial Cancer | Recruiting | 2025-04-04 | 2027-04-04 | ClinicalTrials.gov |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pati… | Phase3 | Non-Small Cell Lung Cancer | Recruiting | 2025-02-27 | 2029-06-01 | ClinicalTrials.gov |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary … | Phase2 | Salivary Gland Cancer | Recruiting | 2025-02-26 | 2027-07-01 | ClinicalTrials.gov |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Phase1 | Glioblastoma | Recruiting | 2025-01-30 | 2030-01-31 | ClinicalTrials.gov |
| NCT06567314 | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | Phase2 | Cutaneous Squamous Cell Carcinoma | Recruiting | 2024-12-02 | 2030-09-01 | ClinicalTrials.gov |
| NCT06429436 | Vending Machine Naloxone Distribution for Your Community (VENDY) | Phase4 | Harm Reduction | Active_Not_Recruiting | 2024-06-01 | 2026-06-30 | ClinicalTrials.gov |
| NCT07225933 | A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal… | — | Urolithiasis | Active_Not_Recruiting | 2024-02-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT06064162 | Ketamine for MS Fatigue | Early_Phase1 | Multiple Sclerosis | Completed | 2023-12-05 | 2025-05-05 | ClinicalTrials.gov |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pati… | Phase3 | Non-Small Cell Lung Cancer | Recruiting | 2023-10-26 | 2029-12-31 | ClinicalTrials.gov |
| NCT06396065 | Phase III Study of AK112 for NSCLC Patients | Phase3 | Non-Squamous Non-small Cell Lung Cancer | Active_Not_Recruiting | 2023-05-04 | 2026-12-31 | ClinicalTrials.gov |
| NCT05382442 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Active_Not_Recruiting | 2022-06-27 | 2028-08-12 | ClinicalTrials.gov |
| NCT04802837 | Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Sub… | Phase3 | Clostridioides Difficile Infection | Terminated | 2021-05-19 | 2022-09-28 | ClinicalTrials.gov |
| NCT04910100 | Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution … | Phase2 | Open-Angle Glaucoma | Completed | 2021-04-15 | 2022-04-29 | ClinicalTrials.gov |
| NCT04761042 | Wilderness Program for Adolescent and Young Adult Cancer Survivors | Na | Cancer | Unknown | 2021-01-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04292301 | MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Hum… | Na | MRI | Completed | 2020-06-30 | 2021-01-07 | ClinicalTrials.gov |
| NCT03595553 | Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficil… | Phase3 | Clostridioides Difficile Infection | Completed | 2019-01-28 | 2021-11-17 | ClinicalTrials.gov |
| NCT03185169 | GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors | Early_Phase1 | Genitourinary Abnormality | Terminated | 2016-11-18 | 2018-07-23 | ClinicalTrials.gov |
| NCT02858362 | Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) i… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2016-06-01 | 2018-09-11 | ClinicalTrials.gov |
| NCT02383511 | Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who F… | Phase1 | Muscular Dystrophy, Duchenne | Completed | 2015-02-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02784002 | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment … | Phase2 | Clostridium Difficile Infection | Completed | 2014-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02092935 | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium D… | Phase2 | Clostridium Difficile Infection | Completed | 2014-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02056808 | A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) | Phase1 | Duchenne Muscular Dystrophy | Completed | 2013-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01759277 | Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthr… | Phase4 | Postoperative Pain Following Knee Arthroplasty | Completed | 2012-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01165437 | Validation of a Novel Oscillometric-Based Algorithm for Determination of the An… | — | Peripheral Arterial Disease | Completed | 2010-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00819598 | Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood P… | — | Peripheral Arterial Disease | Completed | 2009-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00667264 | Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation … | Na | Amputation | Completed | 2008-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00658034 | Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue | Phase3 | Fatigue | Unknown | 2008-04-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00452309 | Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial… | — | Peripheral Arterial Disease | Completed | 2007-03-01 | 2007-08-01 | ClinicalTrials.gov |
Total clinical trials: 54
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| IP PTX | Other | Phase PHASE2 | Phase II | NOT_YET_RECRUITING | NCT07753824 |
| Ivonescimab | Other | Phase PHASE2 | Phase II | NOT_YET_RECRUITING | NCT07753824 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Pleural Mesotheliomas | RECRUITING | NCT06840834 |
| IP PTX | Other | Phase PHASE2 | Phase II | NOT_YET_RECRUITING | NCT07753824 |
| Ivonescimab | Other | Phase PHASE2 | Phase II | NOT_YET_RECRUITING | NCT07753824 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Docetaxel | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Carboplatin | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Ivonescimab | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Ivonescimab | Other | Phase PHASE2 | Phase II | NOT_YET_RECRUITING | NCT07743138 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Hyperbaric Oxygen Therapy (HBOT) | Drug | Phase PHASE2 | Traumatic Brain Injury | RECRUITING | NCT07732374 |
| Placebo Injection | Other | Phase PHASE3 | Non-Squamous Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06396065 |
| AK112 Injection | Other | Phase PHASE3 | Non-Squamous Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06396065 |
| Ivonescimab | Other | Phase PHASE1 | Glioblastoma | RECRUITING | NCT06672575 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| pemetrexed | Other | Phase PHASE2 | Lung Cancer (NSCLC) | RECRUITING | NCT07405190 |
| carboplatin | Other | Phase PHASE2 | Lung Cancer (NSCLC) | RECRUITING | NCT07405190 |
| Ivonescimab | Other | Phase PHASE2 | Lung Cancer (NSCLC) | RECRUITING | NCT07405190 |
| Docetaxel | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Carboplatin | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Ivonescimab | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Questionnaire Administration | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Ivonescimab | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Computed Tomography | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biospecimen Collection | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Digital care | Other | Approved | Pregnancy | RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | RECRUITING | NCT07555093 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Surgical Procedure | Procedure | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Positron Emission Tomography | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Ivonescimab | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Computed Tomography | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Biospecimen Collection | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Standard Learning Methodology | Other | Approved | Workshop | RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | RECRUITING | NCT07607301 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07619339 |
| Tepotinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07619339 |
| Ivonescimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT06567314 |
| Ivonescimab | Other | Phase PHASE1 | Glioblastoma | RECRUITING | NCT06672575 |
| Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Paclitaxel-albumin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Ivonescimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Ivonescimab | Other | Phase PHASE2 | Leiomyosarcoma | RECRUITING | NCT07516925 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | ACTIVE_NOT_RECRUITING | NCT06429436 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07619339 |
| Tepotinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07619339 |
| Questionnaire Administration | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Ivonescimab | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Computed Tomography | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biospecimen Collection | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Ivonescimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT06567314 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Standard Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Genomics & Science Dojo Learning Methodology | Other | Approved | Workshop | NOT_YET_RECRUITING | NCT07607301 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | RECRUITING | NCT07264075 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Experimental: Adductor Canal perineural local anesthetic infusion | Other | Phase PHASE4 | Postoperative Pain Following Knee Arthroplasty | COMPLETED | NCT01759277 |
| Control: Femoral perineural local anesthetic infusion | Other | Phase PHASE4 | Postoperative Pain Following Knee Arthroplasty | COMPLETED | NCT01759277 |
| BLOOD PRESSURE MEASUREMENT | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| BLOOD PRESSURE MEASURMENT | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| BLOOD PRESSURE MEASUREMENT | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| BLOOD PRESSURE MEASURMENT | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| Blood Pressure Measurement | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT01165437 |
| Blood Pressure Measurement | Other | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT01165437 |
| Placebo Acupuncture | Other | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| Acupuncture | Other | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| Placebo Acupuncture | Other | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| Acupuncture | Other | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| SMT C1100 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02056808 |
| SMT C1100 | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | COMPLETED | NCT02383511 |
| Vancomycin | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT02092935 |
| SMT19969 | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT02092935 |
| Fidaxomicin | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT02784002 |
| Ridinilazole | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT02784002 |
| Replens and coconut oil | Other | Phase EARLY_PHASE1 | Genitourinary Abnormality | TERMINATED | NCT03185169 |
| Replens and coconut oil | Other | Phase EARLY_PHASE1 | Genitourinary Abnormality | TERMINATED | NCT03185169 |
| Replens and coconut oil | Other | Phase EARLY_PHASE1 | Genitourinary Abnormality | TERMINATED | NCT03185169 |
| Ezutromid | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT02858362 |
| WAYA-Holiday | Other | Approved | Cancer | UNKNOWN | NCT04761042 |
| WAYA-Wilderness | Other | Approved | Cancer | UNKNOWN | NCT04761042 |
| WAYA-Holiday | Other | Approved | Cancer | UNKNOWN | NCT04761042 |
| WAYA-Wilderness | Other | Approved | Cancer | UNKNOWN | NCT04761042 |
| STrategically Acquired Gradient Echo (STAGE) | Other | Approved | MRI | COMPLETED | NCT04292301 |
| Vancomycin | Other | Phase PHASE3 | Clostridioides Difficile Infection | COMPLETED | NCT03595553 |
| Ridinilazole | Other | Phase PHASE3 | Clostridioides Difficile Infection | COMPLETED | NCT03595553 |
| Vancomycin | Other | Phase PHASE3 | Clostridioides Difficile Infection | TERMINATED | NCT04802837 |
| Ridinilazole | Other | Phase PHASE3 | Clostridioides Difficile Infection | TERMINATED | NCT04802837 |
| Timolol Ophthalmic Solution 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Timolol Ophthalmic Suspension 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 1 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Timolol Ophthalmic Solution 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Timolol Ophthalmic Suspension 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 0.5 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 1 Percent | Other | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| ketamine | Other | Phase EARLY_PHASE1 | Multiple Sclerosis | COMPLETED | NCT06064162 |
| ketamine | Other | Phase EARLY_PHASE1 | Multiple Sclerosis | COMPLETED | NCT06064162 |
| Ivonescimab | Other | Phase PHASE2 | Salivary Gland Cancer | RECRUITING | NCT06805617 |
| Prescription for Action (SPHERES Model) | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07126041 |
| Prescription for Action (SPHERES Model) | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07126041 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | RECRUITING | NCT06959550 |
| Leucovorin | Other | Phase PHASE2 | Stomach Cancer Stage IV | RECRUITING | NCT07070466 |
| Oxaliplatin | Other | Phase PHASE2 | Stomach Cancer Stage IV | RECRUITING | NCT07070466 |
| 5-Fluorouracil | Other | Phase PHASE2 | Stomach Cancer Stage IV | RECRUITING | NCT07070466 |
| Ivonescimab | Other | Phase PHASE2 | Stomach Cancer Stage IV | RECRUITING | NCT07070466 |
| Ivonescimab | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT06925724 |
| Hyperbaric Oxygen Therapy | Drug | Phase PHASE2 | TBI Traumatic Brain Injury | RECRUITING | NCT07214415 |
| Hyperbaric Oxygen Therapy | Drug | Phase PHASE2 | TBI Traumatic Brain Injury | RECRUITING | NCT07214415 |
| 5-fluorouracil | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| Capecitabine | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| Oxaliplatin | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| AK117 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| AK112 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05382442 |
| Questionnaire Administration | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Ivonescimab | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Computed Tomography | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biospecimen Collection | Other | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Thymus Carcinoma | RECRUITING | NCT06980077 |
| FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS) | Other | Preclinical | Urolithiasis | ACTIVE_NOT_RECRUITING | NCT07225933 |
| CVAC® SYSTEM | Other | Preclinical | Urolithiasis | ACTIVE_NOT_RECRUITING | NCT07225933 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| VENDY | Other | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
| FOLFOX regimen | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| Ivonescimab | Other | Phase PHASE2 | Biliary Tract Cancer | RECRUITING | NCT06529718 |
| ivonescimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07234877 |
| Surgical Procedure | Procedure | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Positron Emission Tomography | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Ivonescimab | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Computed Tomography | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Biospecimen Collection | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT07094685 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| FOLFIRI Protocol | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07359456 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06767514 |
| Ivonescimab | Other | Phase PHASE2 | Ivonescimab | RECRUITING | NCT06940518 |
| Ivonescimab | Other | Phase PHASE1 | Glioblastoma | RECRUITING | NCT06672575 |
| Ivonescimab | Other | Phase PHASE2 | Pleural Mesotheliomas | RECRUITING | NCT06840834 |
| Placebo Injection | Other | Phase PHASE3 | Non-Squamous Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06396065 |
| AK112 Injection | Other | Phase PHASE3 | Non-Squamous Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06396065 |
| Pembrolizumab (KEYTRUDA ®) | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | NOT_YET_RECRUITING | NCT07264075 |
| Ligufalimab | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | NOT_YET_RECRUITING | NCT07264075 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE3 | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | NOT_YET_RECRUITING | NCT07264075 |
| Docetaxel | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Carboplatin | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Ivonescimab | Other | Phase PHASE2 | TNBC | RECRUITING | NCT07017673 |
| Drug: Bevacizumab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Drug: Ivonescimab Injection | Drug | Phase PHASE3 | Metastatic Colorectal Cancer (CRC) | RECRUITING | NCT07228832 |
| Ivonescimab | Other | Phase PHASE2 | Leiomyosarcoma | RECRUITING | NCT07516925 |
| Stereotactic Radiosurgery | Procedure | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535463 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535463 |
| Ivonescimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT06567314 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Pembrolizumab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab Injection | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05899608 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Digital care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Standard Care | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Blister pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Bottle pack | Other | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07555093 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| FOLFOX regimen | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab | Other | Phase PHASE2 | Metastatic Esophageal Adenocarcinoma | RECRUITING | NCT06846346 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Osimertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Dato-DXd | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535437 |
| Stereotactic Radiosurgery | Procedure | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535463 |
| Ivonescimab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT07535463 |
| Ivonescimab 20 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| Ivonescimab 10 mg/kg | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07057791 |
| BLOOD PRESSURE MEASUREMENT | PROCEDURE | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| BLOOD PRESSURE MEASURMENT | PROCEDURE | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT00819598 |
| Prescription for Action (SPHERES Model) | OTHER | Approved | Pregnancy | NOT_YET_RECRUITING | NCT07126041 |
| Blood Pressure Measurement | DEVICE | Preclinical | Peripheral Arterial Disease | COMPLETED | NCT01165437 |
| Placebo Acupuncture | PROCEDURE | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| Acupuncture | PROCEDURE | Phase PHASE3 | Fatigue | UNKNOWN | NCT00658034 |
| WAYA-Holiday | OTHER | Approved | Cancer | UNKNOWN | NCT04761042 |
| WAYA-Wilderness | OTHER | Approved | Cancer | UNKNOWN | NCT04761042 |
| Timolol Ophthalmic Solution 0.5 Percent | DRUG | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Timolol Ophthalmic Suspension 0.5 Percent | DRUG | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 0.5 Percent | DRUG | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| Nebivolol Ophthalmic Suspension 1 Percent | DRUG | Phase PHASE2 | Open-Angle Glaucoma | COMPLETED | NCT04910100 |
| ketamine | DRUG | Phase EARLY_PHASE1 | Multiple Sclerosis | COMPLETED | NCT06064162 |
| Hyperbaric Oxygen Therapy | DRUG | Phase PHASE2 | TBI Traumatic Brain Injury | RECRUITING | NCT07214415 |
| VENDY | BEHAVIORAL | Phase PHASE4 | Harm Reduction | RECRUITING | NCT06429436 |
Total products: 605